Alex J Szubert
Overview
Explore the profile of Alex J Szubert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
491
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Riitho V, Connon R, Gwela A, Namusanje J, Nhema R, Siika A, et al.
Nat Commun
. 2024 Jun;
15(1):5492.
PMID: 38944653
One-third of people with HIV in sub-Saharan Africa start antiretroviral therapy (ART) with advanced disease. We investigated associations between immune biomarkers and mortality in participants with advanced HIV randomised to...
2.
Szubert A, Pollock K, Cheeseman H, Alagaratnam J, Bern H, Bird O, et al.
EClinicalMedicine
. 2023 Jan;
56:101823.
PMID: 36684396
Background: Lipid nanoparticle (LNP) encapsulated self-amplifying RNA (saRNA) is well tolerated and immunogenic in SARS-CoV-2 seronegative and seropositive individuals aged 18-75. Methods: A phase 2a expanded safety and immunogenicity study...
3.
Hakim J, Musiime V, Szubert A, Mallewa J, Siika A, Agutu C, et al.
N Engl J Med
. 2017 Jul;
377(3):233-245.
PMID: 28723333
Background: In sub-Saharan Africa, among patients with advanced human immunodeficiency virus (HIV) infection, the rate of death from infection (including tuberculosis and cryptococcus) shortly after the initiation of antiretroviral therapy...
4.
Morgan G, Davies F, Gregory W, Szubert A, Bell S, Drayson M, et al.
Blood
. 2012 Apr;
119(23):5374-83.
PMID: 22498739
The Medical Research Council Myeloma IX Trial (ISRCTNG8454111) examined traditional and thalidomide-based induction and maintenance regimens and IV zoledronic acid (ZOL) and oral clodronate (CLO) in 1960 patients with newly...
5.
Morgan G, Child J, Gregory W, Szubert A, Cocks K, Bell S, et al.
Lancet Oncol
. 2011 Jul;
12(8):743-52.
PMID: 21771568
Background: Bisphosphonates are the standard of care for reducing the risk of skeletal-related events in patients with bone lesions from multiple myeloma. The MRC Myeloma IX study was designed to...
6.
Boyd K, Ross F, Chiecchio L, Dagrada G, Konn Z, Tapper W, et al.
Cancer Epidemiol Biomarkers Prev
. 2011 Jun;
20(8):1703-7.
PMID: 21680536
Background: Several cancer types have differences in incidence and clinical outcome dependent on gender, but these are not well described in myeloma. The aim of this study was to characterize...
7.
Tapper W, Chiecchio L, Dagrada G, Konn Z, Stockley D, Szubert A, et al.
J Clin Oncol
. 2010 Dec;
29(2):e37-9.
PMID: 21135272
No abstract available.
8.
Morgan G, Davies F, Gregory W, Cocks K, Bell S, Szubert A, et al.
Lancet
. 2010 Dec;
376(9757):1989-99.
PMID: 21131037
Background: Bisphosphonates reduce the risk of skeletal events in patients with malignant bone disease, and zoledronic acid has shown potential anticancer effects in preclinical and clinical studies. We aimed to...
9.
Ross F, Chiecchio L, Dagrada G, Protheroe R, Stockley D, Harrison C, et al.
Haematologica
. 2010 Apr;
95(7):1221-5.
PMID: 20410185
A large series of plasma cell dyscrasias (n=2207) was examined for translocations which deregulate the MAF genes, t(14;20)(q32;q12) and t(14;16)(q32;q23), and their disease behavior was compared to a group characterized...